CN1169949C - 一种缺失e1a编码序列的重组腺病毒构建体的获得及用途 - Google Patents
一种缺失e1a编码序列的重组腺病毒构建体的获得及用途 Download PDFInfo
- Publication number
- CN1169949C CN1169949C CNB011446285A CN01144628A CN1169949C CN 1169949 C CN1169949 C CN 1169949C CN B011446285 A CNB011446285 A CN B011446285A CN 01144628 A CN01144628 A CN 01144628A CN 1169949 C CN1169949 C CN 1169949C
- Authority
- CN
- China
- Prior art keywords
- construction body
- adenovirus
- recombinant adenovirus
- adenovirus construction
- recombination
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 241000701161 unidentified adenovirus Species 0.000 title claims abstract description 79
- 238000010276 construction Methods 0.000 title claims abstract description 41
- 230000006798 recombination Effects 0.000 title claims description 30
- 238000005215 recombination Methods 0.000 title claims description 30
- 238000012217 deletion Methods 0.000 title description 2
- 230000037430 deletion Effects 0.000 title description 2
- 206010028980 Neoplasm Diseases 0.000 claims abstract description 22
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 17
- 238000000034 method Methods 0.000 claims abstract description 12
- 108090000790 Enzymes Proteins 0.000 claims abstract description 10
- 102000004190 Enzymes Human genes 0.000 claims abstract description 10
- 108091026890 Coding region Proteins 0.000 claims abstract description 6
- 239000003814 drug Substances 0.000 claims abstract description 5
- 239000013598 vector Substances 0.000 claims abstract description 5
- 238000002703 mutagenesis Methods 0.000 claims abstract description 4
- 231100000350 mutagenesis Toxicity 0.000 claims abstract description 4
- 102000004169 proteins and genes Human genes 0.000 claims abstract description 4
- 238000012408 PCR amplification Methods 0.000 claims abstract description 3
- 238000002360 preparation method Methods 0.000 claims abstract 4
- 239000003153 chemical reaction reagent Substances 0.000 claims abstract 2
- 238000000746 purification Methods 0.000 claims abstract 2
- 230000008034 disappearance Effects 0.000 claims description 16
- 239000013612 plasmid Substances 0.000 claims description 14
- 241000700605 Viruses Species 0.000 claims description 9
- 238000001415 gene therapy Methods 0.000 claims description 9
- 238000004806 packaging method and process Methods 0.000 claims description 6
- 238000005516 engineering process Methods 0.000 claims description 5
- 108010033040 Histones Proteins 0.000 claims description 2
- 230000003321 amplification Effects 0.000 claims description 2
- 238000003199 nucleic acid amplification method Methods 0.000 claims description 2
- 108010024878 Adenovirus E1A Proteins Proteins 0.000 claims 1
- 230000003612 virological effect Effects 0.000 claims 1
- 210000004027 cell Anatomy 0.000 abstract description 31
- 210000004881 tumor cell Anatomy 0.000 abstract description 28
- 230000000694 effects Effects 0.000 abstract description 14
- 238000011282 treatment Methods 0.000 abstract description 12
- 230000002147 killing effect Effects 0.000 abstract description 8
- 238000005520 cutting process Methods 0.000 abstract description 7
- 238000001890 transfection Methods 0.000 abstract description 5
- 241001135569 Human adenovirus 5 Species 0.000 abstract description 3
- 229940079593 drug Drugs 0.000 abstract description 3
- 238000003745 diagnosis Methods 0.000 abstract description 2
- 230000002195 synergetic effect Effects 0.000 abstract description 2
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 abstract 1
- 229960004316 cisplatin Drugs 0.000 abstract 1
- 231100000956 nontoxicity Toxicity 0.000 abstract 1
- 229910052697 platinum Inorganic materials 0.000 description 19
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Substances [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 19
- 230000022534 cell killing Effects 0.000 description 10
- 238000012360 testing method Methods 0.000 description 7
- 238000006243 chemical reaction Methods 0.000 description 6
- 230000008521 reorganization Effects 0.000 description 6
- 238000011161 development Methods 0.000 description 5
- 108700025694 p53 Genes Proteins 0.000 description 5
- 102100025064 Cellular tumor antigen p53 Human genes 0.000 description 4
- 108700025701 Retinoblastoma Genes Proteins 0.000 description 4
- 201000011510 cancer Diseases 0.000 description 4
- 230000002950 deficient Effects 0.000 description 4
- 238000011156 evaluation Methods 0.000 description 4
- 210000004907 gland Anatomy 0.000 description 4
- 238000011160 research Methods 0.000 description 4
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 230000001413 cellular effect Effects 0.000 description 3
- 238000005336 cracking Methods 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 239000012634 fragment Substances 0.000 description 3
- 230000002779 inactivation Effects 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 230000001665 lethal effect Effects 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 230000010076 replication Effects 0.000 description 3
- 108091008146 restriction endonucleases Proteins 0.000 description 3
- 230000001568 sexual effect Effects 0.000 description 3
- 238000001712 DNA sequencing Methods 0.000 description 2
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- 208000004179 Oral Leukoplakia Diseases 0.000 description 2
- 108091000080 Phosphotransferase Proteins 0.000 description 2
- IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 230000004087 circulation Effects 0.000 description 2
- 238000009826 distribution Methods 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 238000003780 insertion Methods 0.000 description 2
- 230000037431 insertion Effects 0.000 description 2
- 210000003292 kidney cell Anatomy 0.000 description 2
- 230000002934 lysing effect Effects 0.000 description 2
- 239000003550 marker Substances 0.000 description 2
- 201000008557 oral mucosa leukoplakia Diseases 0.000 description 2
- 102000020233 phosphotransferase Human genes 0.000 description 2
- 238000012216 screening Methods 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 238000012868 site-directed mutagenesis technique Methods 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- UHDGCWIWMRVCDJ-UHFFFAOYSA-N 1-beta-D-Xylofuranosyl-NH-Cytosine Natural products O=C1N=C(N)C=CN1C1C(O)C(O)C(CO)O1 UHDGCWIWMRVCDJ-UHFFFAOYSA-N 0.000 description 1
- 206010000830 Acute leukaemia Diseases 0.000 description 1
- 208000003200 Adenoma Diseases 0.000 description 1
- 206010001233 Adenoma benign Diseases 0.000 description 1
- 208000010370 Adenoviridae Infections Diseases 0.000 description 1
- 206010060931 Adenovirus infection Diseases 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- DWRXFEITVBNRMK-UHFFFAOYSA-N Beta-D-1-Arabinofuranosylthymine Natural products O=C1NC(=O)C(C)=CN1C1C(O)C(O)C(CO)O1 DWRXFEITVBNRMK-UHFFFAOYSA-N 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 108010031896 Cell Cycle Proteins Proteins 0.000 description 1
- 102000005483 Cell Cycle Proteins Human genes 0.000 description 1
- 206010009944 Colon cancer Diseases 0.000 description 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 1
- 206010010144 Completed suicide Diseases 0.000 description 1
- 102000016736 Cyclin Human genes 0.000 description 1
- 108050006400 Cyclin Proteins 0.000 description 1
- 102100033270 Cyclin-dependent kinase inhibitor 1 Human genes 0.000 description 1
- UHDGCWIWMRVCDJ-PSQAKQOGSA-N Cytidine Natural products O=C1N=C(N)C=CN1[C@@H]1[C@@H](O)[C@@H](O)[C@H](CO)O1 UHDGCWIWMRVCDJ-PSQAKQOGSA-N 0.000 description 1
- 108020004414 DNA Proteins 0.000 description 1
- 206010018338 Glioma Diseases 0.000 description 1
- 101000944380 Homo sapiens Cyclin-dependent kinase inhibitor 1 Proteins 0.000 description 1
- 102000003960 Ligases Human genes 0.000 description 1
- 108090000364 Ligases Proteins 0.000 description 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
- 201000000582 Retinoblastoma Diseases 0.000 description 1
- 241000700584 Simplexvirus Species 0.000 description 1
- 208000026487 Triploidy Diseases 0.000 description 1
- 108700025716 Tumor Suppressor Genes Proteins 0.000 description 1
- 102000044209 Tumor Suppressor Genes Human genes 0.000 description 1
- 241000405217 Viola <butterfly> Species 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 208000011589 adenoviridae infectious disease Diseases 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 description 1
- 229960000074 biopharmaceutical Drugs 0.000 description 1
- 238000009395 breeding Methods 0.000 description 1
- 230000001488 breeding effect Effects 0.000 description 1
- 230000022131 cell cycle Effects 0.000 description 1
- 208000026106 cerebrovascular disease Diseases 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 238000011281 clinical therapy Methods 0.000 description 1
- 101150010855 cma gene Proteins 0.000 description 1
- 201000010989 colorectal carcinoma Diseases 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- UHDGCWIWMRVCDJ-ZAKLUEHWSA-N cytidine Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O1 UHDGCWIWMRVCDJ-ZAKLUEHWSA-N 0.000 description 1
- GDPJWJXLKPPEKK-SJAYXVESSA-N dT4 Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](COP(O)(=O)O[C@@H]2[C@H](O[C@H](C2)N2C(NC(=O)C(C)=C2)=O)COP(O)(=O)O[C@@H]2[C@H](O[C@H](C2)N2C(NC(=O)C(C)=C2)=O)COP(O)(=O)O[C@@H]2[C@H](O[C@H](C2)N2C(NC(=O)C(C)=C2)=O)CO)[C@@H](O)C1 GDPJWJXLKPPEKK-SJAYXVESSA-N 0.000 description 1
- 238000013016 damping Methods 0.000 description 1
- 230000009849 deactivation Effects 0.000 description 1
- 230000002498 deadly effect Effects 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000006073 displacement reaction Methods 0.000 description 1
- 239000000890 drug combination Substances 0.000 description 1
- 238000004043 dyeing Methods 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 208000021045 exocrine pancreatic carcinoma Diseases 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 238000010353 genetic engineering Methods 0.000 description 1
- 208000005017 glioblastoma Diseases 0.000 description 1
- 201000010536 head and neck cancer Diseases 0.000 description 1
- 208000014829 head and neck neoplasm Diseases 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 208000029824 high grade glioma Diseases 0.000 description 1
- 238000002744 homologous recombination Methods 0.000 description 1
- 230000006801 homologous recombination Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 201000005202 lung cancer Diseases 0.000 description 1
- 208000020816 lung neoplasm Diseases 0.000 description 1
- 239000006166 lysate Substances 0.000 description 1
- 230000002101 lytic effect Effects 0.000 description 1
- 201000011614 malignant glioma Diseases 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000001394 metastastic effect Effects 0.000 description 1
- 206010061289 metastatic neoplasm Diseases 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 239000003471 mutagenic agent Substances 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 230000000869 mutational effect Effects 0.000 description 1
- 210000000963 osteoblast Anatomy 0.000 description 1
- 238000012856 packing Methods 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 239000002574 poison Substances 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 230000004853 protein function Effects 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 230000000306 recurrent effect Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000003362 replicative effect Effects 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 238000010008 shearing Methods 0.000 description 1
- 238000002741 site-directed mutagenesis Methods 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 229940104230 thymidine Drugs 0.000 description 1
- 230000007704 transition Effects 0.000 description 1
- 238000013519 translation Methods 0.000 description 1
- MECHNRXZTMCUDQ-RKHKHRCZSA-N vitamin D2 Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)/C=C/[C@H](C)C(C)C)=C\C=C1\C[C@@H](O)CCC1=C MECHNRXZTMCUDQ-RKHKHRCZSA-N 0.000 description 1
- 235000001892 vitamin D2 Nutrition 0.000 description 1
- 239000011653 vitamin D2 Substances 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Images
Landscapes
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
Description
野生型人腺病毒5 | AD5/dE1A | 重组E1、E3缺失腺病毒 | |
U-2OS细胞杀伤率 | |||
第四天 | 50% | 25% | 1% |
第八天 | 100% | 40% | 2% |
第十二天 | 90% | 4% | |
HS700T细胞杀伤率 | |||
第四天 | 70% | 18% | 1% |
第八天 | 100% | 30% | 2% |
第十二天 | 90% | 3% | |
DLD-1细胞杀伤率 | |||
第四天 | 50% | 20% | 1% |
第八天 | 100% | 45% | 2% |
第十二天 | 95% | 4% |
IMR90细胞杀伤率 | |||
第四天 | 50% | 1% | 1% |
第八天 | 100% | 2% | 2% |
第十二天 | 3% | 1% | |
293细胞杀伤率 | |||
第四天 | 50% | 50% | 50% |
第八天 | 100% | 100% | 100% |
第十二天 |
野生型人腺病毒5- + | AD5/dE1A- + | 重组E1、E3缺失腺病毒- + | |
U-2OS细胞杀伤率 | 顺铂(0.2μg/ml) | 顺铂(0.2μg/ml) | 顺铂(0.2μg/ml) |
第四天 | 25% 90% | 25% 93% | 25% 30% |
HS700T细胞杀伤率 | 顺铂(0.2μg/ml) | 顺铂(0.2μg/ml) | 顺铂(0.2μg/ml) |
第四天 | 15% 95% | 15% 95% | 15% 25% |
DLD-1细胞杀伤率 | 顺铂(0.2μg/ml) | 顺铂(0.2μg/ml) | 顺铂(0.2μg/ml) |
第四天 | 18% 92% | 18% 96% | 18% 25% |
IMR90细胞杀伤率 | 顺铂(0.2μg/ml) | 顺铂(0.2μg/ml) | 顺铂(0.2μg/ml) |
第四天 | 5% 80% | 5% 6% | 5% 6% |
293细胞杀伤率 | 顺铂(0.2μg/ml) | 顺铂(0.2μg/ml) | 顺铂(0.2μg/ml) |
第四天 | 15% 95% | 15% 93% | 15% 95% |
Claims (5)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CNB011446285A CN1169949C (zh) | 2001-12-21 | 2001-12-21 | 一种缺失e1a编码序列的重组腺病毒构建体的获得及用途 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CNB011446285A CN1169949C (zh) | 2001-12-21 | 2001-12-21 | 一种缺失e1a编码序列的重组腺病毒构建体的获得及用途 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN1427075A CN1427075A (zh) | 2003-07-02 |
CN1169949C true CN1169949C (zh) | 2004-10-06 |
Family
ID=4677721
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CNB011446285A Expired - Lifetime CN1169949C (zh) | 2001-12-21 | 2001-12-21 | 一种缺失e1a编码序列的重组腺病毒构建体的获得及用途 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN1169949C (zh) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102220292B (zh) * | 2010-04-15 | 2014-08-27 | 中国医学科学院肿瘤研究所 | 重组ii型单纯疱疹病毒、其制备方法及应用和肿瘤诊断试剂盒 |
-
2001
- 2001-12-21 CN CNB011446285A patent/CN1169949C/zh not_active Expired - Lifetime
Also Published As
Publication number | Publication date |
---|---|
CN1427075A (zh) | 2003-07-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2019528691A (ja) | ゲノム編集エンハンサー | |
CN100390292C (zh) | 甲胎蛋白表达细胞的腺病毒载体及其使用方法 | |
US5677178A (en) | Cytopathic viruses for therapy and prophylaxis of neoplasia | |
CN104263703B (zh) | 用于治疗癌症的嵌合腺病毒 | |
US8273344B2 (en) | Recombinant adeno-associated virus expressing human antisense gene CyP2J2 and its preparation methods | |
DE69726759T2 (de) | Cytopatische viren zur therapie und prophylaxe der neoplasie | |
CN102548584A (zh) | 用于治疗癌症的溶瘤腺病毒 | |
CN107208093A (zh) | 用于治疗血红蛋白病的球蛋白基因治疗 | |
CA3076285A1 (en) | Non-integrating dna vectors for the genetic modification of cells | |
HUE026386T2 (en) | Tumor-selective adenovirus E1A and E1B mutants | |
JP2008283982A (ja) | 混在した細胞性組成物からの新生物細胞のウイルスクリアランス | |
EP1326839A2 (en) | Recombinant adenovirus vectors that are replication-competent in tert-expressing cells | |
Brücher et al. | iMATCH: an integrated modular assembly system for therapeutic combination high-capacity adenovirus gene therapy | |
AU2003281310B2 (en) | Tumor-lysing virus growing selectively in tumor cells | |
CN101921769A (zh) | 一种重组腺病毒及其制备方法和应用 | |
CN114317606B (zh) | 靶向人nk细胞的腺病毒载体及其应用 | |
DE602004011487T2 (de) | Modifizierter tert-promotor mit verbesserter tumorspezifität und stärke sowie diesen enthaltender rekombinanter vektor | |
CN1169949C (zh) | 一种缺失e1a编码序列的重组腺病毒构建体的获得及用途 | |
CN1184310C (zh) | 一种联合缺失19Kda、55KDA E1B编码序列重组腺病毒构建体的构建及用途 | |
CN1328372C (zh) | 肿瘤靶向基因-病毒zd55-il-24及其构建方法和应用 | |
CN102399777B (zh) | 一种重组质粒及应用其制备的重组溶瘤腺病毒 | |
Sunila | OF SARCOMA IN THE SOFTSHELL, Mya arenaria | |
CN1053700C (zh) | 家蚕基因工程生产重组人巨噬细胞集落刺激因子 | |
TWI320056B (en) | Virus clearance of neoplastic cells from mixed cellular compositions | |
CN1379109A (zh) | 特异杀伤原发肝癌细胞的腺病毒载体及使用方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C06 | Publication | ||
PB01 | Publication | ||
ASS | Succession or assignment of patent right |
Owner name: SHENZHEN TIANDAKANG GENE ENGINEERING CO., LTD Free format text: FORMER OWNER: ZHOU JIANFENG Effective date: 20030604 |
|
C41 | Transfer of patent application or patent right or utility model | ||
TA01 | Transfer of patent application right |
Effective date of registration: 20030604 Applicant after: Shenzhen Tiandakang Genetic Engineering Co.,Ltd. Applicant before: Zhou Jianfeng |
|
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
CX01 | Expiry of patent term |
Granted publication date: 20041006 |
|
CX01 | Expiry of patent term | ||
DD01 | Delivery of document by public notice |
Addressee: Shenzhen Tiandakang Genetic Engineering Co.,Ltd. Document name: Notice of expiration and termination of patent right |
|
DD01 | Delivery of document by public notice |